The William Harvey Research Institute (WHRI) is led by Professors Mark Caulfield and Amrita Ahluwalia and is located at the historic Charterhouse Square Campus, home to the John Vane Science Centre and the William Harvey Heart Centre.
We are structured into three main areas with several cross-cutting themes across cardiovascular, endocrine and inflammation research.
Research centres and groups
Our research activities are organised around the following centres and groups:
Experimental Medicine & Rheumatology
Led by Professor Costantino Pitzalis the Centre for Experimental Medicine and Rheumatology (EMR) is focused on the development of innovative therapeutic and diagnostic approaches to inflammatory and degenerative arthropathies, particularly rheumatoid and osteoarthritis.
- Professor Constantino Pitzalis
- Dr Michele Bombardieri
- Professor Francesco Dell'Accio
- Dr Mohey Eldin El Shikh
- Dr Frances Humby
- Dr Dylan Morrissey
- Professor Rizgar Mageed
For more information please visit the Centre for Experimental Medicine and Rheumatology
The Centre for Biochemical Pharmacology is successfully investigating key aspects of innate and adaptive inflammation, as well as the mechanisms by which the inflammatory process is resolved published in Immunity, Nature Medicine, Science Translational Medicine amongst others. The Centre has attracted major investments from Research Councils, Charities and EU funding agencies, including 1 MRC and 2 ARUK intermediate and senior fellowships, 3 BHF Intermediate Fellowships, a prestigious Sir Henry Dale Fellowship, and a BHF Chair and Programme Grant.
Led by Professor Sussan Nourshargh the research objective of the Centre for Microvascular Research (CMR) is:
- To investigate the molecular and cellular events within the microvasculature focusing on mechanisms associated with leukocyte trafficking (Nourshargh, Rot & Voisin).
- Regulation of vascular morphology, integrity and function (e.g. permeability) (Nourshargh & Nightingale).
- Vascular generation such as angiogenesis (Whiteford) and myocardial repair and stem cell therapy (Suzuki and Lewis).
- Professor Sussan Nourshargh
- Professor Ken Suzuki
- Professor Antal Rot
- Dr James Whiteford
- Dr Tom Nightingale
- Dr Fiona Lewis
For more information please visit the Centre for Microvascular Research
Translational Medicine & Therapeutics
Translational Medicine aims to improve human health and longevity by moving new preclinical discoveries e.g. of new drugs or other interventions to their evaluation in man (‘bench-to-bedside’). Translational Medicine also seeks to use new knowledge gained in clinical practice and to incorporate clinical observations into scientific hypothesis in the laboratory (‘bed-to-benchside’). The evaluation of new treatments in man will not only inform us about their efficacy but may also lead to a better understanding of the mechanism of action of a drug or lead to the development of new concepts that improve the quality of our preclinical disease models.
The centre comprises of more than 60 members of staff (including PhD-students) which have either a medical background or are basic scientists with a strong interest in applied healthcare research. Our research aims to gain a better understanding of the pathophysiology and ultimately therapy of both acute, critical illnesses (e.g. sepsis, trauma, surgery & perioperative care, acute kidney injury, acute myocardial infarction) as well as chronic diseases (diabetes, chronic kidney disease, pulmonary hypertension, heart failure). Over the years, our preclinical research has led to the discovery of new therapeutics, which are currently being tested in clinical trials in man: COMPARE is a phase II clinical trial that investigates the ‘Combination therapy with racecadotril in pulmonary artery hypertension’, while TOP-ART evaluates (together with the Centre for Trauma Sciences at QMUL) the effects of the anti-malarial drug artesunate in patients with trauma and severe blood loss (together with the Centre for Trauma Sciences at QMUL). We hope that our efforts will improve the care of our patients in East London and well beyond. Our translational efforts have also resulted in the discovery that bicarbonate supplements prevent end-stage kidney disease (already forming part of the guidelines), while our PEAR is evaluating the effects of pentoxyphylline in patients with dialysis and vascular inflammation.
The WHRI offers one of the largest Centres for Clinical Pharmacology in the UK led by Professors Andrew Tinker and Patricia Munroe. Research in Clinical Pharmacology focuses on improving the understanding and treatment of cardiovascular disease. Our strategy combines basic science, ranging from vascular biology, large-scale genetic epidemiology to innovative clinical trials as a route to potential new therapies for cardiovascular disease, prevention of transplant rejection and pain management.
- Professor Andrew Tinker
- Professor Patrica Munroe
- Professor Mark Caulfield
- Professor Amrita Ahluwalia
- Professor Panos Deloukas
- Professor Atholl Johnston
- Professor Anthony Mathur
- Professor Morris Brown
- Professor Andreas Baumbach
- Professor Patricia McGettigan
- Dr Qingzhong Xiao
- Dr Clare Turnbull
- Dr Damien Smedley
- Dr Vikas Kapil
- Dr Livia Carvalho
NIHR Advanced Imaging
Led by Professor Márta Korbonits research activity in the Centre for Endocrinology spans between clinically applied research in endocrinology to basic research in endocrine signalling pathways. The Centre remains one of the leading centres in clinical endocrine research and practice worldwide and has been responsible for many of the current protocols for investigation and management of endocrine disease.
Organisational chart 2017-18